ACIR expands pharmaceutical integration in Central Asia

Institutional integration in the pharmaceutical sector

ACIR Southern Europe continues strengthening its presence in Central Asia through active participation in Kazakhstan’s leading pharmaceutical organizations.

For several months, ACIR has been participating in the National Healthcare Chamber of the Republic of Kazakhstan and the Association for the Support and Development of Pharmaceutical Activities of Kazakhstan. This engagement strengthens cooperation with key market players and expands opportunities between Europe and Central Asia.

A strategic platform for international projects

Participation in these organizations allows ACIR Southern Europe to connect directly with manufacturers, distributors and regulators while contributing international expertise in pharmaceutical, technological and commercial projects implemented across Europe and other regions.

Key areas of cooperation include:

1. Development of international pharmaceutical projects.
2. Regulatory cooperation and market access.
3. Technology transfer and professional training.
4. Expansion of European manufacturers into Central Asia.
5. Participation in innovation and production initiatives.

Benefits for European and Eurasian partners

ACIR Southern Europe’s institutional presence creates significant advantages for partners in both regions.

For Southern European companies:

• direct market access;
• regulatory and commercial support;
• investment opportunity identification;
• strategic partnership development.

For Central Asian partners:

• access to European expertise;
• implementation of innovative technologies;
• cooperation with international manufacturers;
• strengthening of technical and operational capacities.

ACIR Southern Europe continues reinforcing its role as a strategic bridge between Europe and Central Asia in one of the region’s fastest-growing sectors.